Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL10 | P02778 | 1/20 | 0.43 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.43 |
| ▸ | CCL2 | P13500 | 1/20 | 0.43 |
| ▸ | CCL5 | P13501 | 1/20 | 0.43 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.43 |
| ▸ | IGF2R | P11717 | 8/20 | 0.42 |
| ▸ | FGF1 | P05230 | 3/20 | 0.41 |
| ▸ | FGF2 | P09038 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | BDNF | P23560 | 3/20 | 0.35 |
| ▸ | PTN | P21246 | 2/20 | 0.35 |
| ▸ | MDK | P21741 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4957225 | 1.00 | CXCL10 (0.43) | CXCL10CXCL8CCL2CCL5CXCL12 | |
| SCHEMBL9315067 | 0.84 | FGF1 (0.50) | FGF1FGF2CA2F10 | |
| SCHEMBL9314016 | 0.84 | FGF1 (0.50) | FGF1FGF2CA2F10 | |
| SCHEMBL8331004 | 0.81 | FGF1 (0.40) | FGF1FGF2CA2F10BDNF | |
| SCHEMBL9106001 | 0.77 | FGF1 (0.42) | FGF1FGF2CA2F10 | |
| SCHEMBL8781293 | 0.77 | FGF1 (0.42) | FGF1FGF2CA2F10 | |
| SCHEMBL8333531 | 0.77 | SELP (0.44) | FGF1FGF2CA2F10 | |
| SCHEMBL20132940 | 0.75 | BDNF (0.51) | CXCL10CXCL8CCL2CCL5CXCL12 | |
| SCHEMBL20133080 | 0.74 | MAPK1 (0.51) | CXCL12IGF2RCA2BDNFPTN | |
| SCHEMBL5178539 | 0.74 | FGF1 (0.42) | FGF1FGF2CA2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1200484-B1 | METHODS AND REAGENTS MAKING MULTIVALENT ARRAYS AND COMBINATORIAL LIBRARIES OF MULTIVALENT ARRAYS | WISCONSIN ALUMNI RES FOUND (US) | 2011-10-05 | — | — | EP | disclosed |
| US-7138104-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-7018611-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-03-28 | — | — | US | disclosed |
| US-6743412-B2 | ADMINISTERING TO TREAT RHEUMATOID ARTHRITIS, CANCER, RESTENOSIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-6689337-B2 | TARGETING MOIETY OF A QUINOLONE NONPEPTIDE BOUND TO A CHELATOR AND ALSO BINDS TO A RECEPTOR THAT IS UPREGULATED DURING ANGIOGENESIS; IMAGING COMPOUNDS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-6683163-B2 | MONITORING ANGIOGENESIS FACTOR | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-01-27 | — | — | US | disclosed |
| US-20030232053-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2003-12-18 | — | — | US | disclosed |
| US-20030124120-A1 | Quinolone vitronectin receptor antagonist pharmaceuticals | HARRIS THOMAS D (US) | 2003-07-03 | — | — | US | disclosed |
| US-20030113336-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS HOLDINGS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-20030103898-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | LANTHEUS MEDICAL IMAGING, INC. | 2003-06-05 | — | — | US | disclosed |
| US-6511649-B1 | Chemotherapeutic, a radiosensitizer agent, and a targeting moiety bound to chelator and is a quinolone nonpeptide that binds to a receptor; therapeutically effective radioisotope or diagnostically effective imageable moiety; cancer | LANTHEUS MI REAL ESTATE, LLC | 2003-01-28 | — | — | US | disclosed |
| US-6511648-B2 | Diagnosis, therapy cancer | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-28 | — | — | US | disclosed |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MI REAL ESTATE, LLC | 2002-12-05 | — | — | US | disclosed |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MI REAL ESTATE, LLC | 2002-05-23 | — | — | US | disclosed |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2002-04-11 | — | — | US | disclosed |
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | CITIZENS BANK, N.A. | 2002-02-07 | — | — | US | disclosed |
| US-6322770-B1 | FOR DIAGNOSIS AND TREATMENT OF CANCER, IMAGING TUMORS, MONITORING THERAPEUTIC ANGIOGENESIS TREATMENT AND DESTRUCTION OF NEW ANGIOGENIC VASCULATURE; COMPRISED OF TARGETING MOIETY THAT BINDS TO RECEPTOR AND RADIOISOTOPE | DUPONT PHARMACEUTICALS COMPANY | 2001-11-27 | — | — | US | disclosed |
| EP-1140204-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6291616-B1 | POLYMERIZING MONOMER COMPRISING GROUP THAT CAN BE POLYMERIZED THROUGH RING-OPENING METATHESIS POLYMERIZATION IN PRESENCE OF RUTHENIUM OR OSMIUM CARBENE CATALYST TO FORM TEMPLATE; MIXING WITH FUNCTIONALIZED CAPPING AGENT TO FORM POLYMER | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2001-09-18 | — | — | US | disclosed |
| WO-2000035492-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030124120-A1 | Quinolone vitronectin receptor antagonist pharmaceuticals | ADGRF1, QRFPR, ADGRE5 | CXCL10 176/4885CXCL8 1893/4885CCL2 129/4885 |
| US-20030103898-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | TNNI3, ASGR1, TNNT2 | CXCL10 2063/4885CXCL8 1946/4885CCL2 1114/4885 |
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, QRFPR, ADGRE5 | CXCL10 176/4885CXCL8 1893/4885CCL2 129/4885 |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | CXCL10 202/4885CXCL8 1736/4885CCL2 100/4885 |
| US-20030232053-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | CXCL10 200/4885CXCL8 1846/4885CCL2 104/4885 |
| US-20030113336-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | CXCL10 202/4885CXCL8 1736/4885CCL2 100/4885 |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | CXCL10 200/4885CXCL8 1846/4885CCL2 104/4885 |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, RXFP1, VCAM1 | CXCL10 200/4885CXCL8 1846/4885CCL2 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.